SE8901671D0 - Laekemedelsadsorbat - Google Patents

Laekemedelsadsorbat

Info

Publication number
SE8901671D0
SE8901671D0 SE8901671A SE8901671A SE8901671D0 SE 8901671 D0 SE8901671 D0 SE 8901671D0 SE 8901671 A SE8901671 A SE 8901671A SE 8901671 A SE8901671 A SE 8901671A SE 8901671 D0 SE8901671 D0 SE 8901671D0
Authority
SE
Sweden
Prior art keywords
adsorbate
aqueous
laekemedelsadsorbat
ranitidine
chewable
Prior art date
Application number
SE8901671A
Other languages
English (en)
Other versions
SE8901671L (sv
SE508343C2 (sv
Inventor
S J Douglas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888811167A external-priority patent/GB8811167D0/en
Priority claimed from GB888816185A external-priority patent/GB8816185D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE8901671D0 publication Critical patent/SE8901671D0/sv
Publication of SE8901671L publication Critical patent/SE8901671L/sv
Publication of SE508343C2 publication Critical patent/SE508343C2/sv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
SE8901671A 1988-05-11 1989-05-10 Läkemedelsadsorbat SE508343C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888811167A GB8811167D0 (en) 1988-05-11 1988-05-11 Medicaments
GB888816185A GB8816185D0 (en) 1988-07-07 1988-07-07 Medicaments

Publications (3)

Publication Number Publication Date
SE8901671D0 true SE8901671D0 (sv) 1989-05-10
SE8901671L SE8901671L (sv) 1989-11-12
SE508343C2 SE508343C2 (sv) 1998-09-28

Family

ID=26293879

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8901671A SE508343C2 (sv) 1988-05-11 1989-05-10 Läkemedelsadsorbat

Country Status (35)

Country Link
US (1) US5032393A (sv)
JP (1) JP2944678B2 (sv)
KR (1) KR890016968A (sv)
CN (1) CN1027133C (sv)
AT (1) AT401614B (sv)
AU (1) AU624613B2 (sv)
BE (1) BE1002159A5 (sv)
CA (1) CA1337272C (sv)
CH (1) CH679011A5 (sv)
CY (1) CY1781A (sv)
DE (1) DE3915347C2 (sv)
DK (1) DK168934B1 (sv)
ES (1) ES2011573A6 (sv)
FI (1) FI92060C (sv)
FR (1) FR2631232B1 (sv)
GB (1) GB2218333B (sv)
GR (1) GR1000358B (sv)
HK (1) HK45094A (sv)
HU (2) HU204994B (sv)
IE (1) IE60722B1 (sv)
IL (1) IL90245A (sv)
IT (1) IT1232831B (sv)
LU (1) LU87515A1 (sv)
MX (1) MX173349B (sv)
MY (1) MY104013A (sv)
NL (1) NL8901188A (sv)
NO (1) NO175131C (sv)
NZ (1) NZ229064A (sv)
PH (1) PH27612A (sv)
PL (1) PL279377A1 (sv)
PT (1) PT90523B (sv)
RU (1) RU2033155C1 (sv)
SE (1) SE508343C2 (sv)
SG (1) SG48194G (sv)
YU (1) YU47674B (sv)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
GB8925484D0 (en) * 1989-11-10 1989-12-28 Glaxo Group Ltd Process
AU8546591A (en) * 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
JPH06504059A (ja) * 1990-12-21 1994-05-12 リチャードソン、ビックス、インコーポレーテッド ポリアミン薬物−樹脂複合体
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
WO1994008576A1 (en) * 1992-10-16 1994-04-28 Glaxo Group Limited Taste-masking compositions of ranitidine
EP0620001A1 (en) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
JP4283355B2 (ja) * 1997-11-10 2009-06-24 久光製薬株式会社 薬剤用徐放化剤及びそれを含有した徐放性医薬組成物
CA2309597A1 (en) 1997-11-10 1999-05-20 Hiroshi Sorimachi Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same
ATE411047T1 (de) * 1999-07-14 2008-10-15 Schering Plough Ltd Maskieren des geschmacks der oralen flüssigen chinolon-zubereitungen mit ionenaustauscherharzen
US6514492B1 (en) 1999-07-14 2003-02-04 Schering-Plough Veterinary Corporation Taste masking of oral quinolone liquid preparations using ion exchange resins
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020031490A1 (en) * 2000-07-27 2002-03-14 Bellamy Simon Andrew Method for preparing resinates
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
ATE396746T1 (de) * 2002-01-18 2008-06-15 Rohm & Haas Verwendung eines resinats zur herstellung einer formulierung zur beendigung des rauchens
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
WO2007001300A1 (en) * 2005-06-28 2007-01-04 Ucb, S.A. Multiple active drug-resin conjugate
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EP1926736A4 (en) * 2005-09-21 2010-08-25 Chong Kun Dang Pharm Corp NEW RESINATE COMPLEX OF S-CLOPIDOGREL AND METHOD FOR THE PRODUCTION THEREOF
EP2018160B1 (en) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
CN100411626C (zh) * 2006-08-28 2008-08-20 浙江大学 缓释型碘补充剂的制备方法
US8287848B2 (en) 2006-10-03 2012-10-16 Tris Pharma Inc Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
CN100450548C (zh) * 2006-12-22 2009-01-14 江苏奥赛康药业有限公司 一种波拉克林树脂组合物的口腔贴片及其制备方法
MX2010003928A (es) * 2007-10-11 2010-09-10 Philip Morris Prod Producto de tabaco sin humo.
WO2009102830A1 (en) * 2008-02-13 2009-08-20 Eurand Inc Orally disintegrating tablet compositions of ranitidine and methods of manufacture
JP5560701B2 (ja) * 2008-12-26 2014-07-30 ライオン株式会社 ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法
JP5412966B2 (ja) * 2009-06-08 2014-02-12 ライオン株式会社 粒状製剤
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
CN102198118B (zh) * 2011-03-28 2012-08-29 于晓勇 一种治疗呕吐的口腔药物制剂及其制备方法
CN102138915A (zh) * 2011-03-28 2011-08-03 于晓勇 一种口服药物制剂及其制备方法
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
RU2761346C2 (ru) * 2016-11-01 2021-12-07 Джонсон энд Джонсон Консьюмер Инк. Жидкая пероральная фармацевтическая лекарственная форма, содержащая антагонист h2-рецептора гистамина и антацид
EP3784214A4 (en) 2018-04-27 2022-01-19 Johnson & Johnson Consumer Inc. LIQUID ORAL PHARMACEUTICAL DOSAGE FORM

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR803638A (fr) * 1935-06-21 1936-10-05 Système de freinage pour portes coulissantes
US2828207A (en) * 1955-11-14 1958-03-25 Du Pont Fortification of feed
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US2970053A (en) * 1958-10-28 1961-01-31 Pfizer & Co C Oleandomycin resin adsorbate
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3949068A (en) * 1964-02-20 1976-04-06 University Of Alabama In Birmingham Medical And Educational Foundation Pharmaceutical compositions
GB1180233A (en) * 1966-02-23 1970-02-04 Jean Astruc Modified Spiramycin
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
JPS5146154B2 (sv) * 1972-05-11 1976-12-07
GB1462356A (en) * 1973-07-10 1977-01-26 Beecham Group Ltd Pharmaceutical compositions
JPS51125708A (en) * 1974-07-23 1976-11-02 Beecham Group Ltd Production of betaalactam antibiotic complex
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
CY1306A (en) * 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
EP0077529B1 (de) * 1981-10-16 1985-07-17 Sanol Schwarz GmbH Arzneimittelformulierung
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
JPS6369038A (ja) * 1986-09-10 1988-03-29 Canon Inc 光カ−ド記録媒体
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Also Published As

Publication number Publication date
FI892248A0 (sv) 1989-05-10
NO891906D0 (no) 1989-05-10
NZ229064A (en) 1991-12-23
NO175131C (no) 1994-09-07
IT1232831B (it) 1992-03-05
IL90245A (en) 1994-04-12
PT90523B (pt) 1994-10-31
HK45094A (en) 1994-05-13
DE3915347A1 (de) 1989-11-16
IL90245A0 (en) 1989-12-15
YU97189A (en) 1990-06-30
FI92060B (sv) 1994-06-15
CN1027133C (zh) 1994-12-28
DK168934B1 (da) 1994-07-11
CH679011A5 (sv) 1991-12-13
SE8901671L (sv) 1989-11-12
ES2011573A6 (es) 1990-01-16
FI92060C (sv) 1994-09-26
GB2218333A (en) 1989-11-15
HUT50036A (en) 1989-12-28
KR890016968A (ko) 1989-12-14
ATA112089A (de) 1996-03-15
US5032393A (en) 1991-07-16
CY1781A (en) 1995-10-20
PT90523A (pt) 1989-11-30
AU3461789A (en) 1989-11-16
RU2033155C1 (ru) 1995-04-20
IE60722B1 (en) 1994-08-10
CN1037651A (zh) 1989-12-06
GB2218333B (en) 1991-11-06
BE1002159A5 (fr) 1990-08-14
SG48194G (en) 1994-11-25
MX15983A (es) 1993-10-01
AT401614B (de) 1996-10-25
DK229489A (da) 1989-11-12
FR2631232B1 (fr) 1993-11-19
AU624613B2 (en) 1992-06-18
GR1000358B (el) 1992-06-30
MX173349B (es) 1994-01-22
SE508343C2 (sv) 1998-09-28
JP2944678B2 (ja) 1999-09-06
PH27612A (en) 1993-08-31
YU47674B (sh) 1996-01-08
NO891906L (no) 1989-11-13
NL8901188A (nl) 1989-12-01
PL279377A1 (en) 1990-01-22
IT8947938A0 (it) 1989-05-10
GR890100314A (en) 1990-03-12
GB8910706D0 (en) 1989-06-28
IE891527L (en) 1989-11-11
DK229489D0 (da) 1989-05-10
CA1337272C (en) 1995-10-10
FR2631232A1 (fr) 1989-11-17
LU87515A1 (fr) 1990-06-12
HU211592A9 (en) 1995-12-28
DE3915347C2 (de) 1994-11-03
FI892248A (sv) 1989-11-12
HU204994B (en) 1992-03-30
NO175131B (no) 1994-05-30
JPH02111719A (ja) 1990-04-24
MY104013A (en) 1993-10-30

Similar Documents

Publication Publication Date Title
SE8901671D0 (sv) Laekemedelsadsorbat
IT8847556A0 (it) Derivati peptidici, loro preparazione e loro impiego come medicamenti
ES2061799T3 (es) Nuevo preparado medicamentoso y procedimiento para su preparacion.
DK100887A (da) Aminosyrederivater
DE69001730T2 (de) Pastenfoermige, waesserige pharmazeutische zusammensetzungen.
ATE122033T1 (de) Cyancrotonsäureamidverbindung als arzneimittel mit immunmodulierenden eigenschaften.
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
IT8947823A0 (it) Derivati peptidici, loro preparazione e loro impiego come medicamenti
SE8702941L (sv) Farmaceutisk, n-acetyl-cysteininnehallande, vattenloslig komposition
NO910213D0 (no) Fremgangsmaate for fremstilling av orale legemiddelformer av pimobendan.
IT1217445B (it) Composizione farmaceutiche orosolubili contenti acetilcisteina
AU2749288A (en) Use of polysulfated heparins
SE8704952D0 (sv) Farmaceutisk komposition
FI822441L (fi) Pao xantinderivat baserade, magen icke irriterande laekemedelsprodukter och foerfarande foer deras framstaellning
ES2054188T3 (es) Medicamento masticable o chupable, procedimiento para su produccion y aplicacion.
GB2021409A (en) Pharmaceutical composition
DK393788A (da) Substituerede thienoimidazolderivater, fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
TR27058A (tr) 2-azabisiklo (2,2,1) hept-5-ene-2 asetik asid bunun türevleri ve ilgili bilesimleri mezkur bilesimlerin hazirlanmasi usul ve mezkur bilesimlerin n-fosfonometilglisin imali icin kullanilmasi.
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
SE7702078L (sv) Antibiotikom
SE8101963L (sv) Monohydrerad isoftalsyrapikolylamid, forfarande for dess framstellning samt farmaceutisk anvendning derav
DK85490A (da) Krystallinsk (5r,6s)-2-carbamoyloxymethyl-6-((1r)-hydroxyethyl)-2-penemcarboxylsyre og dens farmaceutiske formulering
IT8847578A0 (it) Derivati della pilocarpina, loro preparazione e loro impiego come medicamenti
PT71883B (fr) Procede de preparation de compositions pharmaceutiques a base d'extraits aqueux de marcs des raisins rouges
DK71880A (da) 8-aryl-5,6,7,8-tetrahydropyrazolo (3,4-b) (1,5) diazepin-1h,4h-5,7-dioner, deres fremstilling samt anvendelse som laegemidler

Legal Events

Date Code Title Description
NUG Patent has lapsed